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Abstract
Background: Circulating endothelial cells may serve as novel markers of angiogenesis. These
include a subset of hem-endothelial progenitor cells that play a vital role in vascular growth and
repair. The presence and clinical implications of circulating RNA levels as an expression for
hematopoietic and endothelial-specific markers have not been previously evaluated in preterm
infants. This study aims to determine circulating RNA levels of hem-endothelial marker genes in
peripheral blood of preterm infants and begin to correlate these findings with prenatal
complications.
Methods: Peripheral blood samples from seventeen preterm neonates were analyzed at three
consecutive post-delivery time points (day 3–5, 10–15 and 30). Using quantitative reverse
transcription-polymerase chain reaction we studied the expression patterns of previously
established hem-endothelial-specific progenitor-associated genes (AC133, Tie-2, Flk-1 (VEGFR2) and
Scl/Tal1) in association with characteristics of prematurity and preterm morbidity.
Results: Circulating Tie-2 and SCL/Tal1 RNA levels displayed an inverse correlation to gestational
age (GA). We observed significantly elevated Tie-2 levels in preterm infants born to mothers with
amnionitis, and in infants with sustained brain echogenicity on brain sonography. Other markers
showed similar expression patterns yet we could not demonstrate statistically significant
correlations.
Conclusion: These preliminary findings suggest that circulating RNA levels especially Tie2 and SCL
decline with maturation and might relate to some preterm complication. Further prospective
follow up of larger cohorts are required to establish this association.
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Background
Survival of preterm infants has improved in the last dec-
ades thanks to advances in ventilation strategies, preterm
nutrition and behavioral adaptation. Mortality and mor-
bidity rates, however, are still high, especially in extremely
low birth weight infants (ELBW) [1]. The three most com-
mon morbidities in preterm infants are: bronchopulmo-
nary dysplasia (BPD), which is more prominent in infants
born before 28 weeks of gestation and weighing less than
750–1000 g; retinopathy of prematurity (ROP), which is
still the second most common cause of blindness among
children, and germinal matrix intraventricular hemor-
rhage (GM-IVH) or periventricular leukomalacia (PVL)
that may cause severe complications with long-term con-
sequences, including post-hemorrhagic hydrocephalus,
seizures, cerebral palsy and other neurological deficits.
Vascular pathology is associated with all three conditions
[2,3].
Blood vessel formation occurs through angiogenesis or
vasculogenesis. Until recently, the term vasculogenesis
described the process of blood vessel formation in the
embryo. This occurs via differentiation of precursor cells
(angioblasts) into endothelial cells, which then assemble
into a primitive vascular network [4,5]. First isolated from
peripheral blood in 1997 by Asahara et al [6], endothelial
progenitor cells (EPCs), represent a heterogeneous popu-
lation that expresses hematopoietic and endothelial-spe-
cific markers, including AC133, TIE-2, FLK-1 (VEGFR2)
and SCL/TAL1.
Evidence that EPCs may be involved in endothelial main-
tenance and in neovascularization has led to the examina-
tion of the interaction between pathologic vasculopathy
and EPC [7-9]. These studies proposed that the number of
circulating EPCs is a surrogate biological marker for vascu-
lar function and cumulative cardiovascular risk [10,11] as
well as predictive for outcome in ischemic stroke [12-15].
Only few studies involve EPCs in regard to premature
infants and associated morbidities. Two studies suggested
that modulation of EPCs may have therapeutic potential
in BPD and ROP [16-18].
It was recently demonstrated that the quantification of cir-
culating cells using quantitative reverse transcription PCR
(qRT-PCR) of endothelial molecular markers is consistent
with cell numbers obtained by flow cytometric analysis
[19,20]. This technique provides an efficient tool for the
detection and quantification of these cells similar to the
widely used approach for the detection of circulating
tumor cells in the peripheral blood [21-25].
To date no study has evaluated circulating RNA levels of
hem-endothelial markers in preterm infants. In our
present study we established a quantitative reverse tran-
scription-polymerase chain reaction (qRT-PCR) for the
evaluation of endothelial-specific progenitor-associated
molecular markers e.g. (AC133, Tie-2, Flk-1 (VEGFR2) and
Scl/Tal1) in preterm infants with different characteristics
and in various time points in order to initially determine
C-RNA levels and then provide data of possible associa-
tion to prenatal complication.
Methods
Subjects
All preterm infants sequentially admitted to the neonatal
intensive care unit between June 2006 and January 2007
with a gestational age (GA) less than 34 weeks were eligi-
ble to participate in the study. Infants with major congen-
ital malformations were excluded. The study patients'
characteristics are summarized in Table 1. Informed writ-
ten consent was obtained from the parents. The study was
approved by the ethical committee of the Sheba-Medical-
Center.
Study Protocol
1–1.5 milliliters of blood were drawn into a vacutainer
containing 5.4 milligram potassium ethylenediamine-
tetra-acetic acid (kEDTA) on three consecutive time points
after birth: day 3–5 of life, day 10–15 of life and at 1
month of life. The blood was immediately transferred to
the laboratory. Expression of hem-endothelial-marker
genes was measured by qRT-PCR (namely, AC133, Tie-2,
Flk-1 (VEGFR2) and Scl/Tal1) as well as the angiogenic
growth factor, VEGF.
RNA isolation and cDNA preparation
Blood samples were lysed by Puregene RBC Lysis Solution
(Gentra systems) to remove red cells, and total RNA was
isolated using Trizol reagent (Invitrogen). cDNA was syn-
thesized from total RNA using the Super Script First-
Strand Synthesis System for PCR-RT kit (Invitrogen).
Quantitative real-time reverse transcription-polymerase 
chain reaction
QRT-PCR was performed using a SYBR Green PCR Master
Mix (Applied Biosystems). The qRT-PCR primers used is
shown in Table 2. To eliminate DNA amplification during
qRT-PCR we programmed primers that contained axon
(splice) junctions. In addition, no template cell control
(NTC) was checked in the real-time PCR reactions so as to
ensure the lack of an amplification product indicative of
DNA contamination of the reactions or the formation of
primer dimer. Each PCR reaction contained 100 ng cDNA;
Primer's final concentration was 500 nM each (forward
and reverse). Amplification and detection were performed
with the ABI7900HT sequence detection system (Applied
Biosystem) and analyzed by the SDS 2.1 software. The
thermal cycle used was 2 min at 50°C, 10 min at 95°C,BMC Pediatrics 2009, 9:42 http://www.biomedcentral.com/1471-2431/9/42
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and 40 cycles of 15 sec denaturation at 95°C with 1 min
annealing and extension at 60°C. In order to evaluate tar-
get genes expression, Reverse quantitative (RQ) values
were calculated for each sample. Briefly, the ΔCt value of
the target gene was calculated by subtracting the Ct value
of the reference gene (β-actin)-from the Ct value of the
gene and then normalized against the results obtained
from cord blood of full term infants (ΔΔCt method). All
measurements were preformed in triplicate and an aver-
age result is presented
Statistic
ANOVA analysis with repeated measurements was used to
assess statistically differences in time course of gene
expression levels. The average RQ of the patient groups
were performed using analysis of variance (with con-
founders including GA, birth weight (BW), BPD, ROP,
IVH, and PVL), and the Mann-Whitney test for compari-
son of parametric variables. P value for comparison
between the groups was reported. Values of p ≤ 0.05 was
considered significant. All analyses were preformed using
SPSS version 15 software (SPSS Inc. Chicago. IL, USA).
Results
Twenty one preterm and eight full term infants entered
our study. Three infants were excluded due to technical
difficulties in RNA isolation and one infant died after 48
hours; therefore 17 preterm were eligible for the study.
Table 1 shows the clinical and prenatal characteristics of
the research group. Of the 17 preterm infants, 11 were
Table 1: Patients characteristics
GA BW Sex Delivery PNS Mat amnionitis MV Surf Sepsis A' 1 A' 5 RDS BPD ROP US PVL IVH
26.6 888 M PS Y N Y Y N 2 9 Y N N Y N N
26.4 880 F CS Y N Y Y N 4 8 Y N N Y N N
25.4 724 M CS Y N Y Y Y 7 8 Y N Y Y N N
27.4 1105 M CS Y Y Y Y Y 2 2 Y N N N N N
29.4 980 F CS Y N Y Y N 5 10 Y Y N Y N N
30.5 1325 F CS Y N N N N 9 10 N N N N N N
29.4 1272 F CS Y N Y Y N 5 9 Y N N Y N N
28.2 1115 M PS Y N Y Y Y 6 10 Y N N Y Y Y
30.5 1550 M CS Y N N N N 9 10 N N N N N N
31.6 1835 F CS Y N Y Y N 5 8 Y N N N N N
33.2 1823 M PS Y N N N N 9 10 N N N N N N
32 1378 M CS Y N N N N 6 8 N N N N N N
31.6 1936 M CS Y Y N N N 6 8 N N N N N N
32 1900 M CS Y N N N N 6 7 Y N N N N N
31 1525 M CS Y Y N N N 8 9 N N N N N N
32 2015 M CS Y N Y Y N 9 10 Y N N N N Y
32 2160 F PS Y N N N N 9 10 N N N N N N
GA-gestational age; BW-birth weight; PNS-prenatal amnionitis; Mat amnionitis-maternal amnionitis; MV-mechanical ventilation; SURF-
surfactant; A'1-apgar score at 1 min; A'5-apgar sore at 5 min; RDS-respiratory distress syndrome; BPD-bronchopulmonary dysplasia; ROP-
retinopathy of prematurity; US-head ultrasound Y-increased echogenicity N-normal US; PVL-periventricular leukomalacia; IVH-intraventricular 
hemorrhage; M-male; F-female; Y-yes; N-no; PS-partum spontaneous; CS-cesarean section.BMC Pediatrics 2009, 9:42 http://www.biomedcentral.com/1471-2431/9/42
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males and 6 females with gestational age ranging between
25.4 and 33.2 weeks (average 29.9 ± 2.36 weeks) and BW
between 724 and 2160 g (all were appropriate for GA,
average 1436 ± 450 g). Thirteen of the infants were born
by cesarean section delivery and four were partum sponta-
neous. None of the infants had any major congenital mal-
formations. All mothers of the preterm infants had
antenatal steroid therapy for lung maturation. One
mother had proven amnionitis with positive cultures for
enterococci in the placenta and another two mothers had
suspected amnionitis (maternal fever and leukocytosis).
Three infants had sepsis. Ten infants had respiratory dis-
tress syndrome (RDS) and nine of them were mechani-
cally ventilated and treated with surfactant. Two infants
were diagnosed with mild BPD and one with severe BPD.
Two infants had patent ductus arteriosus (PDA) and were
treated with indomethacin. One infant had ROP grade 3
and was treated with laser photocoagulation. Of the group
of eight full term infants, 7 were born spontaneously and
one by cesarean section due to breech presentation. All
had normal pregnancy and follow up with intact hospital-
ization.
C-RNA levels GA and BW
As GA and BW are important prognostic factors for pre-
term morbidity we looked for an association between C-
RNA levels and these parameters. Only 10 infants had full
results due to laboratory difficulties and insufficient
amount of blood. There was a statistically significant
inverse correlation between GA and circulating Tie2 (Fig-
ure 1, r = -0.597 p = 0.04 Pearson correlation) and SCL
(Figure 1, r = -0.612 p = 0.026 Pearson correlation) mRNA
levels. We found a tendency for an inverse correlation
between BW and the expression levels of all C-RNA at 3–
5 d after birth (Figure 2).
C-RNA levels and brain echogenicity
Serial head ultrasound (US) scans were performed during
the first month of life according to the protocol applied to
all preterm infants admitted to our NICU: an initial ultra-
sound in the first week of life, followed by a second one
10 days later and then a third at one month of age. All
three US were preformed and analyzed by the same pedi-
atric radiology team. Six infants diagnosed with increased
brain echogenicity on their first US: In four infants the
increased echogenicity persist until discharge, one infant
had additionally IVH grade I-II and in one infant the
echogenicity resolved on his last exam. A time dependent
elevation of Tie2 mRNA levels was observed in the six pre-
term infants diagnosed with brain echogenicity (Figure 3).
The difference in Tie2 levels reached statistical significance
at 1 month of age as compared to the levels of Tie2 expres-
sion in those infants with normal brain sonography,
whose Tie2 expression levels remained relatively constant
throughout the study period (0.66 ± 0.1 compared to 0.1
± 0.15 p = 0.035)
C-RNA levels and amnionitis
Three mothers were defined as suffering from clinical
amnionitis (defined as maternal fever and leukocytosis
during delivery) of which one had a positive placenta cul-
ture for enterococci. Although small number of patients-
there was a significant elevation of Tie2 and AC133
expression levels in the blood of preterm infants born to
Table 2: PCR primers used in the present study
Gene Origin Sequence
AC133 Human F 5'-TGGATGCAGAACTTGACAACGT-3'
R '-ATACCTGCTACGACAGTCGTGGT-3'5
VEGF Human F '-AGCCTTGCCTTGCTGCTCTA-3'5
R '-GTGCTGGCCTTGGTGAGG-3'5
VEGFR2 (FLK1) Human F '-GCATCTCATCTGTTACAGC-3'5
R '-CTTCATCAATCTTTACCCC-3'5
SCL Human F '-AGCCGGATGCCTTCCCTAT-3'5
R '-CCGCACAACTTTGGTGTGG-3'5
TIE2 Human F 'GCTTGCTCCTTTCTGGAACTGT-3'5
R '-CGCCACCCAGAGGCAAT-3'5BMC Pediatrics 2009, 9:42 http://www.biomedcentral.com/1471-2431/9/42
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mothers with amnionitis as compared to preterm infants
born to healthy mothers as follows; Tie2: median of
0.05(0.03–0.2) in the absence of amnionitis compared to
0.5 (0.4–2.2) for mothers with amnionitis, p = 0.004 and
AC133: median of 0.04 (0.002–0.4) in the absence of
amnionitis compared to 0.9 (0.09–1.7) for mothers with
amnionitis, p = 0.03)
C-RNA levels in RDS and other preterm morbidities
Ten infants had evidence of RDS: nine were mechanically
ventilated and treated with surfactant and the tenth was
treated with 3 days of oxygen enrichment. No correlation
was found between C-RNA levels and the presence of
RDS, as could be expected due to the vascular independ-
ent pathophysiology that is attributed to RDS.
Discussion
There is a fine balance between the extent of injury and
the capacity of repairing endothelial damage and generat-
ing endothelial cells. Different environmental and inher-
ited factors play a role in this process. Several studies in
adults have shown that EPC levels may be a surrogate bio-
logical marker for angiogenesis and vasculogenesis as well
as regeneration for vascular healing [7,8]. It was previ-
ously demonstrated that derivation of vessels in the post-
natal kidney are from bone marrow-derived circulating
cells [24,26]. Endothelial marker such as Tie2 has also
been established to contribute to post-natal blood vessel
formation [27,28]. Pieh et al have recently shown elevated
plasma levels of the soluble receptor VEGFR-2 and soluble
Tie2 in premature infants with active ROP [18]. In the
present study we established qRT-PCR for the evaluation
of hem-endothelial- associated molecular markers [21-
23,26] in preterm infants. Of course, the mRNA expres-
sion level is not the same as the cell number of EPCs as
few cells may express large amount of a given vascular
marker. Nevertheless, our approach is based on a growing
number of publications which have measured circulating
C-RNA levels and gestational age Figure 1
C-RNA levels and gestational age. Angiogenic marker levels were measured by qRT-PCR in preterm infants with a gesta-
tional age ranging from 24–34 wk as described under "Materials and Methods". Pearson correlation was used to assess the cor-
relation of different angiogenic markers and gestational age. 5 distinctive markers were examined: Tie2 (A), AC133 (B), SCL 
(C), VEGF (D), and FLK (E). The figure depicts the measured RQ for each of the markers measured at 3–5 days after birth in 
comparison to GA (weeks).BMC Pediatrics 2009, 9:42 http://www.biomedcentral.com/1471-2431/9/42
Page 6 of 8
(page number not for citation purposes)
RNA levels of hem-endothelial markers in vascular
pathologies and cancer patients and have shown their lev-
els to be consistent with FACS data enumerating circulat-
ing endothelial cells and EPCs [19-22]. Furthermore,
Benjamin and colleagues have specifically addressed cir-
culating tie-2 RNA levels measured by real-time PCR and
were able to show it as a surrogate marker for vasculogen-
esis [23,29]. Thus, molecular analysis of circulating
marker levels has the potential to reflect angiogenic
potential at the tissue level. Quantitative molecular evalu-
ation offers some distinct advantages. The most important
of which is, that the quantification of RNA can be easily
performed in large series of frozen samples and on small
quantities of blood. These features are of special signifi-
cance when studying preterm infants where blood sam-
ples are difficult to obtain and the amount retrieved is
minimal. In addition, this method allows for better and
more easily achieved inter-laboratory standardization.
This is the first report demonstrating that hem-endothe-
lial-associated molecular marker levels may correlate with
clinical parameters such as gestational age and birth
weight. Notably, our examination of a wide GA range
(25.4–33.2 weeks) demonstrated an inverse relation of
GA to circulating Tie2 and Scl/Tal1 mRNA levels. These
findings indicating possible increased angioblastic activity
in the younger preterm correlates with the well-estab-
lished clinical observation that this specific population
demonstrates higher frequency of cutaneous vascular
lesions compared to older preterms and mature babies.
Brain echogenicity was associated with higher circulating
Tie2 levels in our neonatal population. Increased echo-
genicity has been shown to represent an intracerebral
lesion of an ischemic nature [28] whereas sustained echo-
genicity may have neurodevelopment consequences [30].
Our finding may indicate that C-RNA levels, mainly Tie2,
are involved in the evolution of such ischemic lesions.
This is in agreement with previous studies showing ele-
vated levels of angiogenic markers in patients with
ischemic stroke [13]. Interestingly when grouped
together, infants with vascular-related morbidities (e.g.,
C-RNA levels and birth weight Figure 2
C-RNA levels and birth weight. Angiogenic marker levels were measured by qRT-PCR in preterm infants with a birth 
weights ranging from 724–2160 grams described under "Materials and Methods". Pearson correlation was used to assess the 
correlation of different angiogenic markers and BW. 5 distinctive markers were examined: Tie2, AC133, SCL,, VEGF, FLK. The 
figure depicts the measured RQ for each of the markers measured at 3–5 days after birth in comparison to BW (grams).BMC Pediatrics 2009, 9:42 http://www.biomedcentral.com/1471-2431/9/42
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bronchopulmonary dysplasia, retinopathy of prematu-
rity, intraventricular hemorrhage and skin hemangioma)
have shown a trend towards higher Tie2 RNA levels but
due to the small sample size we could not achieve statisti-
cal differences.
Tie2 is a transmembrane tyrosine kinase protein expressed
principally on vascular endothelium which plays a critical
role in vascular development [31,32]. Disruption of Tie2
function in mice resulted in embryonic lethality associ-
ated with defects in embryonic vasculature, suggesting a
role for Tie2 in blood vessel maturation [33,34]. Moreo-
ver, an activating mutation in the intracellular kinase
domain of the human Tie2 gene has been implicated in
one form of inherited cutaneo-mucosal venous malfor-
mations, further demonstrating the critical function of
Tie2 in vascular development. Over expression of Ang1,
the Tie2 ligand, in mice can increase vascularization in the
skin, whereas delivery of soluble Tie2 can inhibit tumor
angiogenesis [35,34]. Both findings demonstrate that the
activation of the angiopoietin/Tie2 signaling pathway can
lead to excessive angiogenesis. Interestingly, up-regula-
tion of Tie2 mRNA and protein levels, but not of members
of the VEGF/VEGF receptor family, has been observed in
most hemangioma-derived endothelial cells [34]. This
and other studies [35] are consistent with our finding of
the exclusive changes in Tie2 levels but not in the other
markers. Thus, we hypothesize that an increased C-RNA
level, reflected by elevated Tie2, contribute and/or reflects
the formation of excessive and disorganized vasculature
associated with brain echogenicity lesion and possibly
with other progressive and proliferating vascular lesions
found in BPD, ROP and PVL. Further experimental studies
at the tissue levels in murine models are required to sub-
stantiate this hypothesis.
At present, it is not clear whether the elevated circulating
Tie2 transcripts originate from BM-derived endothelial
progenitor cells or, alternatively, if they represent imma-
ture tissue angioblasts or more mature endothelial cells
that are shed from the vessel wall into the circulation dur-
ing vasculogenesis. There is emerging evidence that cells
expressing the combination of CD31, CD45, and Tie-2,
and not CD133/Flk1, comprise a discrete population of
BM-endothelial progenitor cells [36]. Clearly, as the study
only presents RT-PCR data, the cellular origin of the
detected circulating Tie2 mRNA needs to be further inves-
tigated and there is a possibility that multiple cell types
contribute to elevated Tie2 mRNA levels.
Conclusion
In conclusion, the findings of the current study suggest
that angiogenic potential might be demonstrated in rela-
tively higher circulating RNA markers in young preterm
infants and might correlate with the appearance of brain
pathology. Due to the limitation of the restricted study
design in this small preterm population, further prospec-
tive follow up of larger cohorts should define the poten-
tial associations between these laboratory parameters
studied, specifically Tie2 levels, as well as validate the
potential to serve as a surrogate marker for preterm com-
plications and neurodevelopment outcome
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Tie2 mRNA levels and increased brain echogenicity Figure 3
Tie2 mRNA levels and increased brain echogenicity. 
Serial head US scans were performed on all patients in the 
first week of life followed by a second one 10 days later and 
then a third at one month of age. Circulating Tie2 mRNA lev-
els were measured at 3 time points after birth by qRT-PCR 
as described under 'Materials and Methods" in preterm 
infants with normal brain US (A) and in preterm infants with 
increased echogenicity on brain sonography (B). The data 
was analyzed using ANOVA analysis with repeated measure-
ments.BMC Pediatrics 2009, 9:42 http://www.biomedcentral.com/1471-2431/9/42
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